NovaMed to sale Pfizer's anticancer drugs in NovaMed Pharmaceuticals Inc.will sell and promote six anti-tumor drugs in China for Pfizer China, a subsidiary of big pharma company Pfizer Inc.
The contract began in June 2008.
Pfizer China projects that the out-sourcing will...
Pfizer outsources oncology drug sales in China 01-Jul-2008 - Pfizer has enlisted outsourcing services firm NovaMed Pharmaceuticals to conduct the distribution, sales and marketing of some of its products in the country.Under the agreement with Pfizer, NovaMed will serve as the drug giant...
'Trojan horse' crosses blood-brain barrier 30-Jun-2008 - An advance in drug delivery across the blood-brain barrier (BBB) has been made according to research published in PLoS ONE.The Canadian researchers who published the work claim an iron-transport protein, known as p97, can be...
Pfizer outsources oncology drug sales in China - Pfizer has enlisted outsourcing services firm NovaMed Pharmaceuticals to conduct the distribution, sales and marketing of some of its products in the country.Under the agreement with Pfizer, NovaMed will serve as the drug giant's sole...
Pfizer Cuts Costs by Outsourcing Drug Distribution in China NovaMed will sell and promote six anti-tumor drugs in China for Pfizer China, a subsidiary of big pharma company Pfizer Inc.(NYSE: PFE).
The contract began in June 2008.
Pfizer China projects that the out-sourcing will increase its...
Study Shows Rice Bran Arabinoxylan Compound (RBAC) Supplement Sensitizes Human Breast Cancer Cells - Daiwa Pharmaceuticals RBAC exhibits chemo-sensitizing activity against human breast cancer cells in vitro.(Los Angeles, CA) June 27, 2008 A major breakthrough in this area of cancer therapeutics has recently been reported in the Journal...
Delcath Systems to Take on Onyx Pharma's Nexavar Two weeks ago, Delcath Systems Inc (DCTH) that they were in the process of submitting to the FDA a phase III protocol designed to test their Percutaneous Hepatic Perfusion system to deliver high dosages of doxorubicin against Nexavar for...
Hepatitis B Virus - Studies from Nankai University add new findings in the area of hepatitis B virus Hepatitis B Virus Studies from Nankai University add new findings in the area of hepatitis B virus 'The aim of this study is to investigate the molecular mechanism of (HCC) development induced by X (HBx).We previously established a H7402...
Millennium reports positive results from Phase III study of myeloma drug Millennium Pharmaceuticals and the Takeda Oncology Company have presented the updated results from a 482-patient, multi-center, randomized Phase III clinical trial, comparing Velcade and dexamethasone to vincristine, adriamycin and...
Millennium reports positive results from Phase III study of myeloma drug Millennium Pharmaceuticals and the Takeda Oncology Company have presented the updated results from a 482-patient, multi-center, randomized Phase III clinical trial, comparing Velcade and dexamethasone to vincristine, adriamycin and...
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Pa CHICAGO (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ) 'These updated results clearly confirm that the high CR rates with induction therapy improved post-transplantation outcomes, including a decrease in the need for second...
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Pa -- IFM presents updated results from Phase III clinical trial -- CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of updated results from a 482 patient, multi-center,...
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Pa -- IFM presents updated results from Phase III clinical trial -- CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of updated results from a 482 patient, multi-center,...
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Pa CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of updated results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VELCADE and...
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Pa , 6:51 AM EST 'These updated results clearly confirm that the high CR rates with induction therapy improved post-transplantation outcomes, including a decrease in the need for second transplantation,' said Professor Harousseau, M.D., Hotel...
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Pa CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of updated results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VELCADE and...
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Pa CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of updated results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VELCADE and...
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Pa CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of updated results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VELCADE and...
Kids Who Beat Cancer Face Heart Risks -- Kids who beat childhood cancer are five to 10 times more likely than their healthy siblings to develop heart disease in early adulthood, according to the largest study ever to look at the issue.'Childhood cancer survivors in their 20s...
Diagnosis: Cancer, but hope evolving Four years ago, Linda Martin's life turned upside down.During a routine examination, her gynecologist found a lump in one of her breasts.
A mammogram indicated the growth was benign, but Martin's gut told her otherwise.
She insisted a...
BiPar presents positive results from ovarian cancer study The data evaluated BSI-201 as both a single agent and in combination with topotecan in human OVCAR-3 xenografts resistant to adriamycin, melphalan and cisplatin.Administered as monotherapy, BSI-201 demonstrated significant tumor...
